Digital Companion Diagnostics Market Outlook 2026: Trends & Insights According to a newly published market research report by 24LifeSciences, global digital companion diagnostics market was valued at USD 5.2 billion in 2025 and is projected to reach USD 11.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period. Digital companion diagnostics are specialized in vitro diagnostic tests that provide essential information for the safe and effective use of a corresponding therapeutic product. These advanced tools analyze specific biomarkers such as genetic mutations or protein expressions to identify patients who are most likely to benefit from a particular drug or who may be at increased risk of serious side effects. By enabling personalized treatment decisions, these diagnostics are fundamentally transforming patient care, particularly in complex therapeutic areas like oncology, where they guide targeted therapies and immunotherapies with unprecedented precision. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9120/digital-companion-diagnostics-market

Global RSV Diagnostics Market Projected to Grow at a CAGR of 9.4% According to a newly published market research report by 24LifeSciences, global RSV diagnostics market was valued at USD 795 million in 2025 and is projected to grow from USD 870 million in 2026 to reach USD 1,470 million by 2034, growing at a compound annual growth rate (CAGR) of 9.4% during the forecast period. Respiratory Syncytial Virus (RSV) diagnostics encompass the critical tests and methods used to detect the presence of the virus, a leading cause of severe lower respiratory tract infections worldwide. Primarily affecting vulnerable populations such as infants, young children, and older adults, these diagnostics include rapid antigen detection tests (RADTs), molecular assays like PCR, and viral culture techniques, each offering different levels of speed and specificity for clinical decision-making in both hospital and outpatient settings. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9340/rsv-diagnostics-market

Global Bladder Cancer Therapeutics & Diagnostics Market Growing at a CAGR of 7.5% According to a newly published market research report by 24LifeSciences, global bladder cancer therapeutics and diagnostics market was valued at USD 462 million in 2026 and is projected to reach USD 756 million by 2034, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. Bladder cancer therapeutics and diagnostics encompass a wide range of products and technologies essential for detecting, diagnosing, and treating malignancies of the bladder. This includes both critical diagnostic tools such as cystoscopy, urine cytology, advanced imaging, and biomarker tests, as well as therapeutic interventions like intravesical therapies, systemic chemotherapy, immunotherapy, and targeted agents. These solutions are vital for managing a disease that ranks as the 6th most commonly diagnosed cancer in men globally, according to the International Agency for Research on Cancer (IARC). Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8974/bladder-cancer-therapeutics-and-diagnostics-market

Next Generation Cancer Diagnostics Market: Innovation-Driven Growth and Future Opportunities According to a newly published market research report by 24LifeSciences, global next generation cancer diagnostics market was valued at USD 8,060 million in 2026 and is projected to reach USD 28,120 million by 2034, growing at a compound annual growth rate (CAGR) of 20.0% during the forecast period. Next generation cancer diagnostics represent a paradigm shift from traditional histopathology. These advanced technologies enable highly sensitive and specific analysis of cancer biomarkers from various biological samples, with key platforms including Next Generation Sequencing (NGS), qPCR & Multiplexing, and DNA Microarrays. These tools are fundamental for applications such as early detection, companion diagnostics, treatment selection, and minimal residual disease monitoring, enabling a more precise and personalized approach to oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8895/next-generation-cancer-diagnostics-market

Global Rapid Diagnostics Market Expands as Point-of-Care Testing Becomes Central to Healthcare Global rapid diagnostics market is witnessing robust expansion as healthcare systems worldwide prioritize early detection, faster clinical decisions, and decentralized testing models. Valued at approximately USD 46.7 billion in 2024, the market is projected to grow from USD 50.1 billion in 2025 to around USD 76.4 billion by 2032, registering a CAGR of 6.2% during the forecast period. This growth reflects the increasing reliance on rapid diagnostic solutions across hospitals, clinics, and community settings to improve patient outcomes and optimize healthcare efficiency. Access the complete report https://www.24lifesciences.com/rapid-diagnostics-market-9182

What Is the Future of the Prostate Cancer Diagnostics Market? Growth Forecasts & Insights Global prostate cancer diagnostics market is entering a phase of accelerated expansion, driven by rising cancer prevalence, improved screening awareness, and rapid advances in diagnostic technologies. Valued at USD 14.24 billion in 2024, the market is projected to grow from USD 15.43 billion in 2025 to USD 24.78 billion by 2031, registering a strong CAGR of 8.4% during the forecast period. This growth reflects a global shift toward early detection, risk-adapted screening, and precision diagnostics that support better clinical decision-making and patient outcomes. Read the full market study https://www.24lifesciences.com/prostate-cancer-diagnostics-market-6949